Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Open-label, Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated, Metastatic Nonsquamous, Non-small-cell Lung Cancer Patients With CEACAM5-positive Tumors

NCT04154956 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT04154956
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04154956 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Open-label, Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated, Metastatic Nonsquamous, Non-small-cell Lung Cancer Patients With CEACAM5-positive Tumors
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Terminated
Start date
February 6, 2020
Completion date
April 16, 2026
Enrollment
389 (actual)
Sites
169

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer metastatic